Affiliation:
1. Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur-760010, Odisha, India
2. Department of Pharmaceutical Chemistry, Roland Institute of Pharmaceutical Sciences, Berhampur-760010, Odisha, India
Abstract
Background:
Cinacalcet HCl is a calcimimetic, BCS class IV drug with low oral bioavailability.
Polymeric nanoparticles are widely used as biomaterials owing to their biocompatibility, biodegradability,
varied structures, low toxicity, and simple and easy formulation process.
Objective:
The aim of the study was to enhance the oral bioavailability of poorly water-soluble drug,
i.e., cinacalcet HCl, by using a suitable particulate nanocarrier system, i.e., polymeric nanoparticles.
Methods:
Biodegradable Cinacalcet HCl (CH)-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles
were prepared by nanoprecipitation method using Poloxamer-188 as a stabilizer. The experimental
parameters, like polymer concentration, stabilizer concentration, temperature, and RPM speed,
were optimized. An optimized polymeric nanoparticle formulation PNP (F8) was solidified by adsorption
on the porous carrier sylysia 350.
Results:
PNP (F8) exhibited a particle size of 155 nm with low PDI (0.231) and high zeta potential (-
21.3 mV). In vitro diffusion study revealed sustained release of CH for 24 h for both PNP (F8) and solidified
PNP (F8). Pharmacokinetics after oral administration of PNP (F8) and solidified PNP (F8) exhibited
a 5-fold increase in bioavailability. Thus, both PNP (F8) and solidified PNP (F8) showed significant
improvement in oral bioavailability.
Conclusion:
Adsorption of polymeric nanoparticles onto porous carriers like sylysia 350 can be considered
as a promising approach for long-term stability.
Publisher
Bentham Science Publishers Ltd.
Subject
Materials Science (miscellaneous),Biomaterials,Ceramics and Composites
Reference46 articles.
1. Rothe H.M.; Liangos O.; Biggar P.; Petermann A.; Ketteler M.; Cinacalcet treatment of primary hyperparathyroidism. Int J Endocrinol 2011,2011,415719
2. Lindberg J.S.; Culleton B.; Wong G.; Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005,16(3),800-807
3. Cunningham J.; Danese M.; Olson K.; Klassen P.; Chertow G.M.; Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005,68(4),1793-1800
4. Cinacalcet hydrochloride. Available from:
5. Europa.eu. Available from: https://www.ema.europa.eu/en/docu- ments/assessment-report/cinacalcet-accordpharma-epar-public-assessment-report-en